{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:23:13Z","timestamp":1784053393533,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.intimp.2021.107760","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T04:40:51Z","timestamp":1620794451000},"page":"107760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury"],"prefix":"10.1016","volume":"96","author":[{"given":"Lingzhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouke","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2021.107760_b0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41581-018-0052-0","article-title":"Global epidemiology and outcomes of acute kidney injury","volume":"14","author":"Hoste","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107760_b0010","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.kint.2016.10.034","article-title":"Recombinant \u03b1-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy","volume":"91","author":"Hu","year":"2017","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.intimp.2021.107760_b0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nm.2144","article-title":"Epithelial cell cycle arrest in G2\/M mediates kidney fibrosis after injury","volume":"16","author":"Yang","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2021.107760_b0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cphy.c110041","article-title":"Pathophysiology of acute kidney injury","volume":"2","author":"Basile","year":"2012","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107760_b0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1523-1755.2005.00422.x","article-title":"Macrophages and progressive tubulointerstitial disease","volume":"68","author":"Sean Eardley","year":"2005","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.intimp.2021.107760_b0030","doi-asserted-by":"crossref","first-page":"F1187","DOI":"10.1152\/ajprenal.00425.2014","article-title":"Hypoxia as a key player in the AKI-to-CKD transition","volume":"307","author":"Tanaka","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107760_b0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneph.2014.114","article-title":"Inflammatory processes in renal fibrosis","volume":"10","author":"Meng","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2021.107760_b0040","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fphar.2019.00880","article-title":"Combined Blockade of Smad3 and JNK Pathways Ameliorates Progressive Fibrosis in Folic Acid Nephropathy","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107760_b0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41419-020-02876-1","article-title":"Upregulation of miR-382 contributes to renal fibrosis secondary to aristolochic acid-induced kidney injury via PTEN signaling pathway","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.107760_b0050","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1681\/ASN.2015020225","article-title":"RNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis","volume":"27","author":"Craciun","year":"2016","journal-title":"JASN"},{"issue":"3","key":"10.1016\/j.intimp.2021.107760_b0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.toxlet.2013.11.014","article-title":"Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis","volume":"224","author":"Stallons","year":"2014","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.intimp.2021.107760_b0060","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1681\/ASN.2016111222","article-title":"Targeting Phospholipase D4 Attenuates Kidney Fibrosis","volume":"28","author":"Trivedi","year":"2017","journal-title":"JASN"},{"issue":"1","key":"10.1016\/j.intimp.2021.107760_b0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.23876\/j.krcp.2018.37.1.30","article-title":"Human CD36 overexpression in renal tubules accelerates the progression of renal diseases in a mouse model of folic acid-induced acute kidney injury","volume":"37","author":"Jung","year":"2018","journal-title":"Kidney Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.intimp.2021.107760_b0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrendo.2015.122","article-title":"Metabolic functions of FABPs\u2014mechanisms and therapeutic implications","volume":"11","author":"Hotamisligil","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107760_b0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2021.107760_b0080","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejmech.2017.07.022","article-title":"Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review","volume":"138","author":"Floresta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.intimp.2021.107760_b0085","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.2174\/0929867325666181008154622","article-title":"Role of Fatty Acid Binding Protein 4 (FABP4) in Kidney Disease","volume":"27","author":"Shi","year":"2020","journal-title":"CMC"},{"issue":"9","key":"10.1016\/j.intimp.2021.107760_b0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.numecd.2014.03.006","article-title":"Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction","volume":"24","author":"Ebert","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107760_b0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc08-1333","article-title":"Circulating Levels of Adipocyte and Epidermal Fatty Acid-Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients","volume":"32","author":"Yeung","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.intimp.2021.107760_b0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2018.07.006","article-title":"Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated Breast\/Mammary Tumor Development","volume":"28","author":"Hao","year":"2018","journal-title":"Cell Metab."},{"issue":"27","key":"10.1016\/j.intimp.2021.107760_b0105","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1039\/C8RA00122G","article-title":"Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury","volume":"8","author":"Shi","year":"2018","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.intimp.2021.107760_b0110","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1111\/jcmm.14512","article-title":"Pharmacological and genetic inhibition of fatty acid\u2010binding protein 4 alleviated cisplatin\u2010induced acute kidney injury","volume":"23","author":"Tan","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.intimp.2021.107760_b0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fphar.2018.00917","article-title":"Pharmacological Inhibition of Fatty Acid-Binding Protein 4 (FABP4) Protects Against Rhabdomyolysis-Induced Acute Kidney Injury","volume":"9","author":"Huang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107760_b0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1523-1755.2005.00151.x","article-title":"EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism","volume":"67","author":"Li","year":"2005","journal-title":"Kidney Int."},{"issue":"7147","key":"10.1016\/j.intimp.2021.107760_b0125","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2021.107760_b0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-050214-013407","article-title":"Acute Kidney Injury","volume":"67","author":"Zuk","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107760_b0135","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.7150\/thno.31424","article-title":"EGFR drives the progression of AKI to CKD through HIPK2 overexpression","volume":"9","author":"Xu","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2021.107760_b0140","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bbrc.2017.11.106","article-title":"FABP4 induces asthmatic airway epithelial barrier dysfunction via ROS-activated FoxM1","volume":"495","author":"Wu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2021.107760_b0145","doi-asserted-by":"crossref","first-page":"L227","DOI":"10.1152\/ajplung.00429.2017","article-title":"FABP4 regulates eosinophil recruitment and activation in allergic airway inflammation","volume":"315","author":"Ge","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107760_b0150","first-page":"604","article-title":"FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation","volume":"1863","author":"Bosquet","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids"},{"issue":"13","key":"10.1016\/j.intimp.2021.107760_b0155","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.1074\/jbc.M413788200","article-title":"The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity","volume":"280","author":"Makowski","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2021.107760_b0160","doi-asserted-by":"crossref","first-page":"F1107","DOI":"10.1152\/ajprenal.00179.2018","article-title":"Divergent effects of AKI to CKD models on inflammation and fibrosis","volume":"315","author":"Black","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.intimp.2021.107760_b0165","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1681\/ASN.2017121283","article-title":"Interleukin-1beta Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis","volume":"29","author":"Lemos","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4 suppl 2","key":"10.1016\/j.intimp.2021.107760_b0170","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and Renal Disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"JASN"},{"issue":"1","key":"10.1016\/j.intimp.2021.107760_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11745-007-3111-z","article-title":"Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene Transcription","volume":"43","author":"Schroeder","year":"2008","journal-title":"Lipids"},{"issue":"14","key":"10.1016\/j.intimp.2021.107760_b0180","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1128\/MCB.22.14.5114-5127.2002","article-title":"Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription","volume":"22","author":"Tan","year":"2002","journal-title":"MCB"},{"key":"10.1016\/j.intimp.2021.107760_b0185","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2337\/db13-0436","article-title":"FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues","volume":"63","author":"Garin-Shkolnik","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2021.107760_b0190","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2174\/156802608784535084","article-title":"PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?","volume":"8","author":"Feldman","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2021.107760_b0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.atherosclerosis.2015.03.042","article-title":"FABP4 inhibition suppresses PPAR\u03b3 activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages","volume":"240","author":"Bo\u00df","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.intimp.2021.107760_b0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000069764","article-title":"Negative growth effects of ciglitazone on kidney interstitial fibroblasts: role of PPAR-gamma","volume":"26","author":"Parameswaran","year":"2003","journal-title":"Kidney Blood Press Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.107760_b0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1074-7613(04)00030-5","article-title":"Transcriptional Inactivation of STAT3 by PPAR\u03b3 Suppresses IL-6-Responsive Multiple Myeloma Cells","volume":"20","author":"Wang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107760_b0210","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/961753","article-title":"A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer","volume":"2008","author":"Yang","year":"2008","journal-title":"PPAR Res."},{"issue":"8","key":"10.1016\/j.intimp.2021.107760_b0215","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"RICOTE","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.intimp.2021.107760_b0220","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41419-019-1610-5","article-title":"FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism","volume":"10","author":"Qiao","year":"2019","journal-title":"Cell Death Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:07:09Z","timestamp":1727291229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921003969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":44,"alternative-id":["S1567576921003969"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107760","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107760"}}